The evaluation of antimicrobial stewardship for bacterial meningitis in neonates

Abstract

Bacterial meningitis (BM) is potentially life threatening in neonates, but the duration of antibiotic therapy is not well established. We aimed to compare the efficacy and safety among neonates suffering from BM of a relatively shortened duration of antibiotic treatment to the currently recommended course. We did a retrospective cohort study in neonates (gestational age [GA] or corrected GA ≥35 weeks) diagnosed with BM. Neonates in the study group were assigned to withdraw the antibiotics on condition that they were clinically stable after taking sufficient antibiotics with normal serological inflammatory biomarkers, whereas the cerebrospinal fluid (CSF) indicators remain abnormal. Neonates in the control group were treated until both serological and CSF indicators returned to normal as recommended. The incidence of recurrent infection after the discontinuation of antibiotics and adverse drug reactions (ADRs) during hospitalization was measured. A total of 233 neonates were enrolled, of whom 160 were assigned to a shortened antibiotic duration and 73 were treated according to the current guidelines. Twelve patients (7.5%) relapsed in the study group, whereas 4 (5.5%) relapsed in the control group (χ² = 0.320, p = 0.572). The incidences of ADRs were similar in both groups (p > 0.05). The study indicates that antibiotics might be safely discontinued in neonates (GA ≥35 weeks) diagnosed with BM who are clinically stable or improving after antibiotic treatment and feature normal serological inflammatory markers, no severe complications, and no evidence of systemic infection, even if CSF parameters are not completely normal.

Keywords

antimicrobial stewardship / CNS infections / meningitis / neonate

References

[1] Hasbun R. Progress and challenges in bacterial meningitis: a review. JAMA. 2022;328(21):2147-2154.

[2] Baud O, Aujard Y. Neonatal bacterial meningitis. Handb Clin Neurol. 2013;112:1109-1113.

[3] Furyk JS, Swann O, Molyneux E. Systematic review: neonatal meningitis in the developing world. Trop Med Int Health. 2011;16(6):672-679.

[4] Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. Lancet Infect Dis. 2017;17(8):867-872.

[5] Biondi EA, Lee B, Ralston SL, et al. Prevalence of bacteremia and bacterial meningitis in febrile neonates and infants in the second month of life: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(3):e190874.

[6] Okike IO, Johnson AP, Henderson KL, et al. Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United Kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance. Clin Infect Dis. 2014;59(10):e150-e157.

[7] Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177(9):1308-1315.

[8] Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301-306.

[9] Geer MI, Koul PA, Tanki SA, Shah MY. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. J Pharmacol Toxicol Methods. 2016;81:323-334.

[10] Pratico AD, Longo L, Mansueto S, et al. Off-label use of drugs and adverse drug reactions in pediatric units: a prospective, multicenter study. Curr Drug Saf. 2018;13(3):200-207.

[11] Cuzzolin L, Agostino R. Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study. Eur J Clin Pharmacol. 2016;72(1):117-123.

[12] Xu M, Hu L, Huang H, et al. Etiology and clinical features of full-term neonatal bacterial meningitis: a multicenter retrospective cohort study. Front Pediatr. 2019;7:31.

[13] Zhao Z, Yu JL, Zhang HB, Li JH, Li ZK. Five-year multicenter study of clinical tests of neonatal purulent meningitis. Clin Pediatr. 2018;57(4):389-397.

[14] McMullan BJ, Andresen D, Blyth CC, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis. 2016;16(8):e139-e152.

[15] van Ettekoven CN, van de Beek D, Brouwer MC. Update on community-acquired bacterial meningitis: guidance and challenges. Clin Microbiol Infect. 2017;23(9):601-606.

[16] Karageorgopoulos DE, Valkimadi PE, Kapaskelis A, Rafailidis PI, Falagas ME. Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. Arch Dis Child. 2009;94(8):607-614.

[17] Molyneux E, Nizami SQ, Saha S, et al. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet. 2011;377(9780):1837-1845.

[18] Mathur NB, Kharod P, Kumar S. Evaluation of duration of antibiotic therapy in neonatal bacterial meningitis: a randomized controlled trial. J Trop Pediatr. 2015;61(2):119-125.

[19] Wang D, Guo H, Jin JP, et al. Clinical and cerebrospinal fluid follow-up of 25 cases of community-acquired acute bacterial meningitis with abnormal cerebrospinal fluid when antibiotics discontinued. Nat Sci J Nanjing Med Univ. 2017;37(07):880-882. (in Chinese).

[20] Vaswani ND, Gupta N, Yadav R, Nadda A. Seven versus ten days antibiotics course for acute pyogenic meningitis in children: a randomized controlled trial. Indian J Pediatr. 2021;88(3):246-251.

[21] Yu JL, Yu HM. The expert consensus on diagnosis and treatment of neonatal septicemia (2019 edition). Chin J Pediatr. 2019(04):252-257. (in Chinese).

[22] Lin MC, Chiu NC, Chi H, Ho CS, Huang FY. Evolving trends of neonatal and childhood bacterial meningitis in northern Taiwan. J Microbiol Immunol Infect. 2015;48(3):296-301.

[23] Srinivasan L, Kilpatrick L, Shah SS, Abbasi S, Harris MC. Cerebrospinal fluid cytokines in the diagnosis of bacterial meningitis in infants. Pediatr Res. 2016;80(4):566-572.

[24] Tan J, Kan J, Qiu G, et al. Clinical prognosis in neonatal bacterial meningitis: the role of cerebrospinal fluid protein. PLoS One. 2015;10(10):e0141620.

[25] van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22(Suppl 3):S37-S62.

[26] Swanson D. Meningitis. Pediatr Rev. 2015;36(12):514-524. quiz 525-516.

[27] Lyons TW, Cruz AT, Freedman SB, et al. Correction of cerebrospinal fluid protein in infants with traumatic lumbar punctures. Pediatr Infect Dis J. 2017;36(10):1006-1008.

[28] Bilal A, Taha MK, Caeymaex L, Cohen R, Levy C, Durrmeyer X. Neonatal meningococcal meningitis in France from 2001 to 2013. Pediatr Infect Dis J. 2016;35(11):1270-1272.

[29] Lucas MJ, Brouwer MC, van de Beek D. Neurological sequelae of bacterial meningitis. J Infect. 2016;73(1):18-27.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children's Hospital of Chongqing Medical University.